The triple therapy inhalers market is projected to grow from USD 12.5 billion in 2026 to USD 24.8 billion by 2036, at a CAGR of 7.1%. Triple Combination (ICS + LABA + LAMA) will dominate with a 60.0% market share, while dry powder inhalers will lead the device type segment with a 45.0% share.